Marius

Marius Pharmaceuticals is a commercial-stage pharmaceutical company focused on the development and commercialization of therapies for testosterone deficiency. The company's flagship product, KYZATREX, is an oral testosterone undecanoate formulation approved by the FDA for treating adult males with primary or hypogonadotropic hypogonadism. Marius utilizes a proprietary delivery technology that facilitates lymphatic absorption, bypassing the liver to reduce potential hepatotoxicity. The company is dedicated to improving patient outcomes in men's health through convenient and effective oral treatment options. By providing an alternative to injections and gels, Marius aims to increase patient compliance and quality of life.